Enoxacin is a new naphthyridine fluoroquinolone antibiotic with potent activity in vitro against many gram-positive and gram-negative bacteria (10, 18) . Studies in normal volunteers have demonstrated that the bioavailabilities of several newer fluoroquinolones, including enoxacin, exceed 70% (12, 16, 22) ; however, the pharmacokinetics and bioavailabilities of many of these agents in elderly infected patients are not known. This study examined the pharmacokinetics of enoxacin in a group of elderly patients with complicated urinary tract infections (UTIs) who received enoxacin as an intravenous (i.v.)-to-oral regimen.
MATERIALS AND METHODS Patients. The patient population comprised elderly men with complicated UTIs enrolled in a clinical trial evaluating the efficacy of enoxacin. A complicated UTI was defined by the presence of one or more of the following: urinary tract obstruction, urologic malignancy, neurogenic urologic disease, or recent instrumentation of the genitourinary tract. Patients excluded from the study included those with terminal illnesses or concomitant infections potentially precluding evaluation of response, liver function tests or a serum creatinine greater than twice the upper limit of normal, inability to accept orally administered medications, chronic antacid therapy, and a known or suspected allergy to quinolones.
Drug administration. Patients were initially treated with 400 mg of enoxacin i.v. every 12 h. The drug was diluted in 250 ml of 5% glucose in water and infused into a peripheral vein over 1 h by using a constant-rate infusion pump. The * Corresponding author.
i.v. tubing was flushed with an additional 20 ml of 5% glucose in water at the end of the infusions to ensure complete delivery of the dose. After at least 72 h of parenteral therapy, patients were changed to oral therapy with 400-mg enoxacin tablets every 12 h. The total duration of therapy was 10 to 14 days.
Timing of pharmacokinetic studies. Pharmacokinetic studies were performed after patients had received five or more doses by the i.v. and oral routes to assess steady-state pharmacokinetic conditions. Trough blood samples for enoxacin were obtained from all patients prior to the administration of the two doses preceding the study dose to confirm steady-state pharmacokinetic conditions. On Drug assay. The enoxacin concentrations in plasma and urine were determined by high-performance liquid chromatography (HPLC). The mobile phase consisted of a mixture of HPLC-grade acetonitrile (Aldrich Chemical Co., Inc., Milwaukee, Wis.) with an ion-pair reagent (16:84 [vol/vol) . The ion-pair reagent was prepared by combining 21 g of citric acid monohydrate (Fisher Scientific Co., Fairlawn, N.J.) and 1 g of ammonium perchlorate (Aldrich) in a 1-liter flask. To this dry fraction, 1.15 ml of tetrabutylammonium hydroxide (Aldrich) in 100 ml of HPLC-grade water was added and further diluted to 1 liter with water. This mixture was then degassed by filtering it twice through 0.2-,um-poresize Nylon-66 filters (Rainin Instrument Co., Woburn, Mass.) under vacuum.
A reversed-phase, 25-cm, partisil 5 ODS-3 analytical column (Whatman International Ltd., Maidstone, England) was used. The mobile phase was passed through the column at a flow rate of 1.0 ml/min. A hand-packed guard column of C-18 pellicular material (Whatman), which was repacked with fresh material every 2 to 3 assay days, was also used. The UV A340 was detected (model 481 LC spectrophotometer; Waters Associates, Inc., Milford, Mass.). Enoxacin standards in plasma or urine were prepared fresh each assay day. Standard concentrations in plasma ranged from 0.2 to 5.0 mg/liter, while standard concentrations in urine ranged from 10 to 300 mg/liter. Norfloxacin (Merck Sharp & Dohme, West Point, Pa.) stock solutions of 30 and 100 mg/liter were used as internal standards in the plasma and urine assays, respectively.
Plasma standards and samples were prepared by pipetting 0.4 ml of plasma, 0.1 ml of water, and 0.02 ml of internal standard into a 2-ml polypropylene centrifuge tube. Protein precipitation with 0.1 ml of acetonitrile-perchloric acid (4:1 [vol/vol]) was followed by a 10-min centrifugation at 700 x g (IEC, Needham Heights, Mass.) at 25°C. The supernatant was used for assay. Urine standards and samples were prepared by adding 0.1 ml of urine to 0.8 ml of HPLC-grade water and 0.1 ml of internal standard.
Column retention times for norfloxacin and enoxacin were 7.5 and 9.0 min, respectively. Enoxacin and norfloxacin peak heights were calculated and recorded by using an electronic integrator (LCI 100; The Perkin-Elmer Corp., Norwalk, Conn.). Peak height ratios (enoxacin to norfloxacin) were calculated and regressed against concentrations of known standards by least-squares linear regression.
The within-and between-day coefficients of variation for assay precision of three plasma controls containing 0. 25 (Table 1 ) and experienced acute, unexplained increases in his blood urea nitrogen and serum creatinine along with electrolyte abnormalities during the study that were not thought to be related to enoxacin. Because this patient was thought to be an outlier, parameter values for this patient were excluded when means for the study population were calculated. Parameter values for patient 2 are included in the reported ranges in Table 2 .
When data for patient 2 were excluded from the group analysis, mean (range) peak and trough enoxacin concentrations in plasma following i.v. and oral dosing were 8.15 mg/liter (range, 5.5 to 11.1 mg/liter) and 2.31 mg/liter (range, 0.4 to 4.7 mg/liter) and 5.45 mg/liter (range, 2.3 to 6.6 mg/liter) and 2.19 mg/liter (range, 0.5 to 4.7 mg/liter), respectively, in the nine patients. The mean time to reach peak concentrations following oral dosing was 2 h, but it varied between 0.5 and 6 h. This variability in time to reach peak concentrations accounts for an artifactual "second peak" in the mean plasma enoxacin concentration-time curve following oral dosing (Fig. 1) ; a second peak was not observed in individual curves.
The oral F of enoxacin in these patients ranged between 66.5 and 113.1%, with an average of about 87% ( Table 2) . Application of a correction factor to the AUC ratios for slight changes in noncompartmental elimination t1/2 (t0122) between the i.v. and oral phases had little impact on the calculated bioavailability. The mean fractions of the administered dose excreted unchanged in the urine in six patients with complete 12-h urine collections were 50.6 and 50.0% following i.v. and oral dosing, respectively, when corrected for F.
Noncompartmental pharmacokinetic analysis. Noncompartmental pharmacokinetic data were analyzed following i.v. and oral administration, and the results are given in mg/liter, respectively, over the same collection intervals.
In the nine patients included in the group analysis, enoxacin CL (or CL/F following oral dosing) averaged 2.58 ml/min per kg (range, 1.0 to 4.84 ml/min per kg) and 3.01 ml/min per kg (range, 1.50 to 6.07 mllmin per kg) following i.v. and oral dosing, respectively. The enoxacin CLR was approximately 1.4 ml/min per kg by either route of administration and explained approximately half of the CL. The Creatinine Clearance (ml/min) (21) . The pharmacokinetics of the fluoroquinolones have been extensively studied in young, normal volunteers or young patients; however, relatively few studies have characterized the disposition of these compounds in elderly patients receiving therapy with these drugs. Issues such as the reliability of oral absorption and the absence of drug accumulation are important considerations for the use of these drugs in this patient population.
In this study, high enoxacin bioavailability was demonstrated in elderly infected patients. Following the distribution and absorption phases after i.v. and oral administration, respectively, enoxacin plasma concentration-versustime curves were practically superimposable. The amount of drug excreted in urine, another marker of drug absorption for agents excreted by the renal route, further demonstrated excellent bioavailability following oral dosing. Marked variability in the time to reach maximum concentration in plasma following oral dosing was observed; however, the variation in absorption time did not appear to affect the overall extent of enoxacin absorption within each patient.
These results are comparable to those of other investigations of enoxacin pharmacokinetics in elderly patients. In a group of 19 patients (ages, 61 to 84 years) with complicated UTIs, Naber and colleagues (15) In evaluating the pharmacokinetics of enoxacin in our elderly patients, a smaller V and decreased CLR were noted with the values reported in younger subjects. These pharmacokinetic differences are likely due to the well-described changes in physiology associated with advancing age, particularly decreases in total body water and lean body mass and, perhaps most importantly, a decline in renal function (9, 14) . These changes result in higher peak drug concentrations, larger AUCs, and prolonged t1/2S of certain drugs in this patient population (9, 14) . The change in enoxacin CLR with CLCR in our patients was similar to that observed by others studies in which elderly patients as well as younger patients with renal impairment were evaluated (3, 17, 23) . The relation between decreased enoxacin clearance with declining renal function was vividly demonstrated in patient 2 in this study, highlighting the importance of dosage alterations in similar patients.
A few studies have directly compared fluoroquinolone pharmacokinetics in young and elderly subjects. For a single 600-mg oral dose of enoxacin, Dobbs et al. (5) found that maximum concentrations in plasma and AUCs were statistically higher in a group of elderly subjects compared with a group of younger controls; however, enoxacin t1/2s were not different between the groups (7.34 and 6.75 h for the young and elderly subjects, respectively). Other investigations of ofloxacin (8) and pefloxacin (6) (fluoroquinolones with markedly different mechanisms of elimination [17] ) revealed significant pharmacokinetic differences between young and elderly subjects. Substantially higher peak drug concentrations and prolonged drug elimination were found in the elderly subjects in both studies.
Comparative pharmacokinetic studies of ciprofloxacin (an agent similar to enoxacin in that excretion is balanced between renal and nonrenal mechanisms) in young and elderly subjects also indicate age-related differences. Ball and co-workers (1) found significantly greater maximum concentratiQns in serum and AUCs in an elderly group of Ratients following single 100-mg oral doses. LeBel et al. (13) studied ciprofloxacin pharmacokinetics in young and elderly (age;-70 to 86 years) subjects following single 500-mg oral doses. Mean peak concentrations in serum 8 h after dosing and mean AUCs were found to be significantly higher in the elderly subjects. The t1/2 was approximately double in the elderly patient group (6.8 h) compared with that in the young volunteers,. (3.7 h ). These differences were explained by significantly smaller volumes of distribution at steady state and reduced clearances (both CLR and nonrenal clearance) in the elderly patient group compared with those in the younger subjects.
The clinical significance of these pharmacokinetic differences between young and elderly individuals may be realized only through integration with the dose-or concentrationrelated adverse. effects and pharmacodynamic characteristics of the fluoroquinolones. Correlations between fluoroquinolone concentrations and adverse effects, such as those of the central nervous system, remain poorly defined. Wolf et al. (25j noted that higher doses -of enoxacin (1,600 mg), which resulted in peak concentration's in serum of 7 to 8 mg/liter, were associated with adverse central nervous system effects (dizziness) in several volunteers more frequently than lower doses were. Further studies are needed to better define the possible relations between concentrations of drug in serum and adverse effects.
In vitro and animal studies evaluating the pharmacokinetics of the antibacterial activities of fluoroquinolones suggest that dosing regimens that produce high peak concentrations may be optimal. This suggestion is based on a number of characteristics of the fluoroquinolones, including concentration-dependent killing and the observation of a significant postantibiotic effect in vitro and in vivo against a number a bacteria (M. N. Dudley, Postgrad. Med., in press). In addition, high peak concentrations have been shown to reduce the emergence of resistant subpopulations in an in vitro model of infectiond (2) . To take advantage of these pharmacokinetic and pharmacodynamic characteristics, particularly in elderly patients, the optimal dosing strategy for these antibiotics may be through administration of usual doses less frequently (i.e., once daily), since a given dose in elderly patients produces a higher peak concentration (compared with that in a young individual) and elimination of the drug is prolonged.
